Moderna to ask U.S., European regulators to OK its vaccine

Moderna also said it would “apply for a conditional marketing authorisation with the European Medicines Agency (EMA).”

November 30, 2020 06:19 pm | Updated 06:31 pm IST - New York

Vials with a sticker reading “COVID-19/Coronavirus Vaccine/Injection only” are seen in front of a Moderna logo in this illustratin photo. File

Vials with a sticker reading “COVID-19/Coronavirus Vaccine/Injection only” are seen in front of a Moderna logo in this illustratin photo. File

Moderna Inc. said it would ask U.S. and European regulators on Monday to allow emergency use of its COVID-19 vaccine as new study results confirm the shots offer strong protection — ramping up the race to begin limited vaccinations as the coronavirus rampage worsens.

Multiple vaccine candidates must succeed for the world to stamp out the pandemic, which has been on the upswing in the U.S. and Europe. U.S. hospitals have been stretched to the limit as the nation has seen more than 160,000 new cases per day and more than 1,400 daily deaths.

Also read: Coronavirus vaccine | Pfizer could get U.K. approval this week, says Telegraph

Since first emerging nearly a year ago in China, the virus has killed more than 1.4 million people worldwide.

Moderna is just behind Pfizer and its German partner BioNTech in seeking to begin vaccinations in the U.S. in December. Across the Atlantic, British regulators also are assessing the Pfizer shot and another from AstraZeneca.

Also read: Coronavirus | ‘Covishield’ vaccine volunteer sues Serum Institute of India, Oxford Group over ‘adverse reaction’

Moderna created its shots with the U.S. National Institutes of Health and already had a hint they were working, but said it got the final needed results over the weekend that suggest the vaccine is more than 94% effective.

Of 196 COVID-19 cases so far in its huge U.S. study, 185 were trial participants who received the placebo and 11 who got the real vaccine. The only people who got severely ill — 30 participants, including one who died — had received dummy shots, said Dr. Tal Zaks, the Cambridge, Massachusetts, company’s chief medical officer.

Also read: Coronavirus | First ‘wave’ of COVID-19 vaccination to cover 30 crore Indian

When he learned the results, “I allowed myself to cry for the first time,” Zaks told The Associated Press . “We have already, just in the trial, have already saved lives. Just imagine the impact then multiplied to the people who can get this vaccine.”

Moderna said the shots’ effectiveness and a good safety record so far — with only temporary, flu-like side effects — mean they meet requirements set by the U.S. Food and Drug Administration for emergency use before the final-stage testing is complete. The European Medicines Agency, Europe’s version of FDA, has signaled it also is open to faster, emergency clearance.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.